Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products...

Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals. In February 2020 after receiving details of the genetic sequence...

to Inovio Pharmaceuticals' INO-3112 immunotherapy, currently in Phase I/II, under an agreement which could net more than US$727.5 million for Inovio. INO-3112...

PMID 26386540. "Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer". www.inovio.com. Inovio Pharmaceuticals. Archived...

Retrieved August 8, 2016. "Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial". Inovio Pharmaceuticals. July 26, 2016. Archived from...

as of 2009 and 2010 include Theraclone, VaxInnate, Crucell NV, Inovio Pharmaceuticals, Immune Targeting Systems (ITS) and iQur. In 2019, Distributed Bio...

for SARS-CoV-2, being: Moderna, Inovio Pharmaceuticals, and the University of Queensland (UQ). By February 2020, Inovio announced that it had produced...

likely not be sufficient to eradicate HCV completely. As of 2020, Inovio Pharmaceuticals is developing a synthetic multi-antigen DNA vaccine covering HCV...

therapies: In October 2018, the foundation awarded $8,279,723 to Inovio Pharmaceuticals to fund the development of "next-generation" delivery methods for...

began testing at the National Institutes of Health. Separately, Inovio Pharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine...